XTAE
ALBA
Market cap182mUSD
Oct 09, Last price
3,009.00ILS
1D
-2.61%
1Q
3.91%
Jan 2017
-46.37%
Name
Al-Bad Massuot Yitzhak Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Albaad Massuot Yitzhak Ltd is a global producer and distributor of a wide variety of wet wipe products. Its extensive range includes personal hygiene items such as disinfecting and antibacterial hand wipes, as well as cosmetic wipes tailored for facial, body, and foot care. The company also offers feminine hygiene products, notably tampons, alongside wipes designed for babies, maternity needs, toddlers, and general household cleaning. Additionally, Albaad provides specialized professional wipes for para-medical, veterinary, automotive, and restaurant use, often supplied in sachet format. Its offerings further extend to adult bed and bath wipes, intimate personal care wipes, para-pharmaceutical wipes, and flushable moist toilet paper. Beyond its own brand portfolio, the company delivers contract, private label, and institutional manufacturing services. Founded in 1985, Albaad Massuot Yitzhak Ltd is headquartered in Nir Yitzhak, Israel.
Key people
Amnon Barodie
Chairman of the Board, President · since 2005
Zvika Avigad
Caesarea Site Manager · since 2018
Dror Meir
Manager of Cloth Division · since 2015
Shlomo Shaubi
Manager of Products Plant · since 2015
Tanbush Wolfgang
Chief Executive Officer of Albaad Deutschland GmbH · since 2004
Efraim Bazia
Vice President - Finance · since 2016
Nachum Levavi
General Manager - Israel · since 2008
Shmuel Hacohen
Director of Sales, Director of Marketing · since 2010
Ronit Lavi
Director of Human Resources · since 2015
Internal Auditor · since 2017
Yaron Levkovich
General Counsel, Secretary · since 2014
Beni Karen
Director · since 2015
Shimon Laufer
Director · since 2015
Michael Lazar
Director · since 2005
Director · since 2011
Itzhak Raviv
Director · since 2010
Yosy Elshech
External Director · since 2005
External Director · since 2019
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||